Holen Sie sich die Stockscreener-App
4.24
0.95%
-0.0407
Handel nachbörslich:
4.24
Inmed Pharmaceuticals Inc Aktie (INM) Neueste Nachrichten
InMed Pharmaceuticals Reports Improved Quarterly Earnings - TipRanks
InMed Pharmaceuticals (STU:MWG) Debt-to-EBITDA : -0.13 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Growth Rank : 0 (As of Nov. 17, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Issuance of Stock : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Working Capital : €-0.33 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Repurchase of Stock : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventory-to-Revenue : 0.95 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Financing : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Deferred Tax : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EBITDA Growth Rate : 70.10% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Retained Earnings : €-101.33 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) ROE % Adjusted to Book Value : -14.96% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 50-Day SMA : €4.49 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) FCF Yield % : -226.50 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PE Ratio without NRI : At Loss (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Volatility : 115.20% (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Capex-to-Operating-Cash-Flo - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Momentum Rank : 3 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year FCF Growth Rate : 71.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBITDA per Share : €-24.28 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Gross Profit : €1.02 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Revenue per Share : €12.67 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Day RSI : 43.89 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Enterprise Value : €-2.41 Mil (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Rate of Return (Yac - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Peter Lynch Fair Value : €-607.53 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Assets : €10.98 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 5-Year EBITDA Growth Rate : 55.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Days Payable : 57.29 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Debt-to-Equity : 0.11 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 14-Day RSI : 47.30 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Graham Number : €N/A (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Inventories : €1.16 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) GF Value Rank : 0 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 9-Day RSI : 45.74 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-Revenue : -0.57 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBITDA : €-6.98 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) PE Ratio (TTM) : At Loss (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-FCF : 0.37 (As of Nov. 16, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Preferred Stock : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Free Cash Flow per Share : €-22.21 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Dividends per Share : €0.00 (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Financial Strength : 5 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Shares Outstanding (EOP) : 8.92 Mil (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) PE Ratio (TTM) : At Loss (As of Nov. 15, 2024) - GuruFocus.com
ARMISTICE CAPITAL, LLC Acquires New Holdings in InMed Pharmaceuticals Inc - GuruFocus.com
InMed Pharmaceuticals stock hits 52-week high at $4.67 - Investing.com India
InMed Pharmaceuticals Inc. (INM) Quarterly 10-Q Report - Quartz
InMed Pharmaceuticals Makes Progress on Alzheimer’s Drug - TipRanks
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile
InMed Pharmaceuticals stock hits 52-week high at $4.67 By Investing.com - Investing.com Canada
InMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest Up 188.8% in October - Defense World
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules - Newsfile
InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing | INM Stock News - StockTitan
New Zealand Dollar/Indian Rupee (NZDINR) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com Canada
InMed Pharmaceuticals granted Nasdaq compliance extension - Investing.com
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Global Gold EW Index (TXGE) QuotePress Release - The Globe and Mail
Pilgrim's Pride (PPC-Q) QuotePress Release - The Globe and Mail
InMed files patent for Alzheimer's drug candidate INM-901 - Investing.com India
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease - Newsfile
InMed Pharmaceuticals’ New Alzheimer’s Treatment Patent - TipRanks
InMed Pharmaceuticals Announces Appointment of Dr. Barry Greenberg to Scientific Advisory Board - Defense World
TSX Financials Capped Index (TTFS) QuotePress Release - The Globe and Mail
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease - Newsfile
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):